Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Coagulation Disorders | 2 | 2020 | 102 | 1.110 |
Why?
|
| Hemorrhagic Disorders | 4 | 2022 | 24 | 1.080 |
Why?
|
| Menorrhagia | 4 | 2022 | 78 | 1.060 |
Why?
|
| Autoimmune Diseases | 2 | 2026 | 262 | 0.780 |
Why?
|
| Pathologists | 1 | 2021 | 27 | 0.690 |
Why?
|
| Gastritis | 2 | 2021 | 374 | 0.690 |
Why?
|
| Telerehabilitation | 1 | 2020 | 10 | 0.650 |
Why?
|
| Neuroendocrine Tumors | 3 | 2026 | 70 | 0.630 |
Why?
|
| Hematology | 1 | 2020 | 44 | 0.620 |
Why?
|
| von Willebrand Diseases | 4 | 2022 | 54 | 0.620 |
Why?
|
| Factor V Deficiency | 1 | 2019 | 2 | 0.610 |
Why?
|
| alpha-2-Antiplasmin | 1 | 2019 | 4 | 0.610 |
Why?
|
| Fibrinolysis | 1 | 2019 | 44 | 0.600 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2019 | 49 | 0.590 |
Why?
|
| Gastric Mucosa | 2 | 2021 | 494 | 0.580 |
Why?
|
| Tranexamic Acid | 1 | 2019 | 30 | 0.580 |
Why?
|
| Antifibrinolytic Agents | 1 | 2019 | 46 | 0.580 |
Why?
|
| Stress, Psychological | 1 | 2020 | 536 | 0.450 |
Why?
|
| Caregivers | 1 | 2020 | 598 | 0.420 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2020 | 629 | 0.410 |
Why?
|
| Anxiety | 1 | 2020 | 1014 | 0.400 |
Why?
|
| Parents | 1 | 2020 | 1128 | 0.380 |
Why?
|
| Depression | 1 | 2020 | 1320 | 0.340 |
Why?
|
| Precancerous Conditions | 2 | 2025 | 281 | 0.290 |
Why?
|
| Hemorrhage | 3 | 2022 | 487 | 0.270 |
Why?
|
| Blood Preservation | 2 | 2019 | 29 | 0.260 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2022 | 402 | 0.230 |
Why?
|
| Fatty Liver | 2 | 2025 | 224 | 0.230 |
Why?
|
| Liver Cirrhosis | 2 | 2025 | 903 | 0.230 |
Why?
|
| Anus Neoplasms | 1 | 2025 | 40 | 0.220 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2025 | 37 | 0.220 |
Why?
|
| Adenocarcinoma | 2 | 2026 | 972 | 0.220 |
Why?
|
| Gastritis, Atrophic | 1 | 2026 | 65 | 0.220 |
Why?
|
| von Willebrand Factor | 3 | 2022 | 191 | 0.220 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2024 | 20 | 0.210 |
Why?
|
| Pancreas | 1 | 2025 | 217 | 0.210 |
Why?
|
| Urea Cycle Disorders, Inborn | 1 | 2025 | 83 | 0.210 |
Why?
|
| Parietal Cells, Gastric | 1 | 2024 | 38 | 0.200 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2025 | 196 | 0.190 |
Why?
|
| Humans | 27 | 2026 | 131163 | 0.190 |
Why?
|
| Erythrocytes | 2 | 2019 | 186 | 0.170 |
Why?
|
| Papillomavirus Infections | 1 | 2025 | 394 | 0.170 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2020 | 10 | 0.160 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2020 | 6 | 0.160 |
Why?
|
| Cryptosporidiosis | 1 | 2021 | 35 | 0.160 |
Why?
|
| Health Care Surveys | 1 | 2021 | 276 | 0.160 |
Why?
|
| Female | 19 | 2026 | 70963 | 0.160 |
Why?
|
| Receptors, Estrogen | 1 | 2024 | 732 | 0.160 |
Why?
|
| Granulosa Cell Tumor | 1 | 2020 | 38 | 0.160 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 33 | 0.160 |
Why?
|
| India | 1 | 2020 | 234 | 0.150 |
Why?
|
| Stomach Neoplasms | 1 | 2026 | 572 | 0.150 |
Why?
|
| Home Care Services | 1 | 2020 | 73 | 0.150 |
Why?
|
| Blood Platelets | 2 | 2019 | 313 | 0.150 |
Why?
|
| Income | 1 | 2020 | 138 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2025 | 750 | 0.150 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2019 | 32 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2025 | 740 | 0.150 |
Why?
|
| Workload | 1 | 2020 | 151 | 0.150 |
Why?
|
| Cerebral Palsy | 1 | 2020 | 86 | 0.150 |
Why?
|
| Stem Cells | 1 | 2024 | 702 | 0.150 |
Why?
|
| Attitude to Health | 1 | 2020 | 247 | 0.150 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 136 | 0.140 |
Why?
|
| Microfluidics | 1 | 2019 | 31 | 0.140 |
Why?
|
| Postpartum Hemorrhage | 1 | 2020 | 111 | 0.140 |
Why?
|
| Diagnostic Errors | 2 | 2020 | 345 | 0.140 |
Why?
|
| Diethylnitrosamine | 1 | 2018 | 20 | 0.140 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2018 | 8 | 0.140 |
Why?
|
| Phenobarbital | 1 | 2018 | 32 | 0.140 |
Why?
|
| Prospective Studies | 4 | 2025 | 6459 | 0.140 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2018 | 65 | 0.140 |
Why?
|
| Plasma | 1 | 2019 | 102 | 0.140 |
Why?
|
| Thrombelastography | 1 | 2019 | 69 | 0.140 |
Why?
|
| Blood Coagulation | 1 | 2019 | 134 | 0.140 |
Why?
|
| Erythrocyte Transfusion | 2 | 2019 | 146 | 0.140 |
Why?
|
| Inheritance Patterns | 1 | 2018 | 127 | 0.140 |
Why?
|
| Thyroid Gland | 1 | 2018 | 96 | 0.140 |
Why?
|
| Ovary | 1 | 2020 | 345 | 0.130 |
Why?
|
| Anemia | 1 | 2022 | 354 | 0.130 |
Why?
|
| Feeding Behavior | 1 | 2023 | 715 | 0.130 |
Why?
|
| Prevalence | 2 | 2025 | 2701 | 0.130 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 248 | 0.130 |
Why?
|
| Esophageal Mucosa | 1 | 2017 | 12 | 0.130 |
Why?
|
| Liver | 1 | 2025 | 1796 | 0.130 |
Why?
|
| Down Syndrome | 1 | 2020 | 233 | 0.130 |
Why?
|
| Mental Health | 1 | 2020 | 378 | 0.130 |
Why?
|
| Spinal Dysraphism | 1 | 2020 | 261 | 0.120 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2017 | 65 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 420 | 0.120 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1928 | 0.120 |
Why?
|
| Helicobacter pylori | 2 | 2026 | 1373 | 0.120 |
Why?
|
| Esophagoscopy | 1 | 2017 | 180 | 0.120 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 335 | 0.120 |
Why?
|
| Metabolome | 1 | 2019 | 326 | 0.120 |
Why?
|
| Helicobacter Infections | 2 | 2026 | 1313 | 0.120 |
Why?
|
| Colonic Polyps | 1 | 2017 | 82 | 0.120 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2015 | 35 | 0.120 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 241 | 0.110 |
Why?
|
| Biopsy | 3 | 2026 | 1239 | 0.110 |
Why?
|
| Hemolysis | 1 | 2015 | 86 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2023 | 3061 | 0.110 |
Why?
|
| Developmental Disabilities | 1 | 2020 | 781 | 0.110 |
Why?
|
| Autism Spectrum Disorder | 1 | 2020 | 450 | 0.110 |
Why?
|
| Colonoscopy | 1 | 2017 | 243 | 0.110 |
Why?
|
| Adult | 11 | 2026 | 31282 | 0.110 |
Why?
|
| Middle Aged | 9 | 2026 | 28601 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 262 | 0.100 |
Why?
|
| Adolescent | 6 | 2025 | 20987 | 0.100 |
Why?
|
| Age Factors | 1 | 2020 | 2825 | 0.100 |
Why?
|
| Child | 4 | 2025 | 26341 | 0.100 |
Why?
|
| Barrett Esophagus | 1 | 2017 | 357 | 0.100 |
Why?
|
| Male | 10 | 2026 | 64957 | 0.100 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 388 | 0.090 |
Why?
|
| Nitric Oxide | 1 | 2015 | 471 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2015 | 523 | 0.090 |
Why?
|
| Healthy Volunteers | 2 | 2019 | 154 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2025 | 15110 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 4697 | 0.070 |
Why?
|
| Cystadenoma, Serous | 1 | 2025 | 14 | 0.060 |
Why?
|
| Diet | 2 | 2023 | 1121 | 0.060 |
Why?
|
| Formaldehyde | 1 | 2025 | 49 | 0.060 |
Why?
|
| Argininosuccinic Aciduria | 1 | 2025 | 53 | 0.060 |
Why?
|
| Gastric Acid | 1 | 2024 | 73 | 0.050 |
Why?
|
| Fast Foods | 1 | 2023 | 26 | 0.050 |
Why?
|
| Bile Duct Neoplasms | 1 | 2024 | 130 | 0.050 |
Why?
|
| Aged | 3 | 2026 | 21025 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2023 | 414 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2024 | 349 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2904 | 0.040 |
Why?
|
| Sex Factors | 1 | 2026 | 1356 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 421 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2025 | 1445 | 0.040 |
Why?
|
| Metaplasia | 1 | 2021 | 215 | 0.040 |
Why?
|
| Salpingo-oophorectomy | 1 | 2020 | 10 | 0.040 |
Why?
|
| Forkhead Box Protein L2 | 1 | 2020 | 10 | 0.040 |
Why?
|
| Risk Factors | 2 | 2026 | 11074 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2025 | 17753 | 0.040 |
Why?
|
| von Willebrand Disease, Type 2 | 1 | 2019 | 4 | 0.040 |
Why?
|
| Plasticizers | 1 | 2019 | 3 | 0.040 |
Why?
|
| Oxidants | 1 | 2019 | 24 | 0.040 |
Why?
|
| Health Behavior | 1 | 2022 | 387 | 0.040 |
Why?
|
| Diarrhea | 1 | 2021 | 301 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2026 | 3359 | 0.040 |
Why?
|
| Swine, Miniature | 1 | 2018 | 52 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2019 | 95 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 2018 | 65 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 315 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 775 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 254 | 0.030 |
Why?
|
| Hysterectomy | 1 | 2020 | 202 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2019 | 178 | 0.030 |
Why?
|
| Carcinogens | 1 | 2018 | 127 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2018 | 237 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 136 | 0.030 |
Why?
|
| Incidence | 1 | 2026 | 3360 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 226 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2019 | 190 | 0.030 |
Why?
|
| Time Factors | 2 | 2019 | 6196 | 0.030 |
Why?
|
| Texas | 1 | 2026 | 3686 | 0.030 |
Why?
|
| Feces | 1 | 2021 | 721 | 0.030 |
Why?
|
| Exome | 1 | 2022 | 1061 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2019 | 267 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 311 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2025 | 1147 | 0.030 |
Why?
|
| Plethysmography | 1 | 2015 | 34 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2015 | 60 | 0.030 |
Why?
|
| Exercise | 1 | 2022 | 892 | 0.030 |
Why?
|
| Acetylcholine | 1 | 2015 | 69 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 1186 | 0.030 |
Why?
|
| Vasodilation | 1 | 2015 | 175 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 3829 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 1287 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 4066 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 2304 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3385 | 0.020 |
Why?
|
| Young Adult | 1 | 2025 | 10103 | 0.020 |
Why?
|
| Animals | 2 | 2024 | 33912 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 5063 | 0.020 |
Why?
|
| United States | 1 | 2026 | 12072 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7512 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 18301 | 0.020 |
Why?
|
| Mutation | 1 | 2020 | 6099 | 0.020 |
Why?
|